These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


127 related items for PubMed ID: 1859883

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High-dose intravenous immunoglobulin treatment activates complement in vivo.
    Mollnes TE, Høgåsen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R.
    Scand J Immunol; 1998 Sep; 48(3):312-7. PubMed ID: 9743219
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
    Basta M, Kirshbom P, Frank MM, Fries LF.
    J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.
    Basta M, Langlois PF, Marques M, Frank MM, Fries LF.
    Blood; 1989 Jul; 74(1):326-33. PubMed ID: 2752117
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
    Hwang HY, Duvall MR, Tomlinson S, Boackle RJ.
    Mol Immunol; 2008 May; 45(9):2570-80. PubMed ID: 18313756
    [Abstract] [Full Text] [Related]

  • 10. Surfactant protein A regulates complement activation.
    Watford WT, Wright JR, Hester CG, Jiang H, Frank MM.
    J Immunol; 2001 Dec 01; 167(11):6593-600. PubMed ID: 11714829
    [Abstract] [Full Text] [Related]

  • 11. The interaction of immune serum globulin and immune globulin intravenous with complement.
    Bing DH.
    Mol Immunol; 1983 Aug 01; 20(8):893-900. PubMed ID: 6604863
    [Abstract] [Full Text] [Related]

  • 12. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro.
    Mollnes TE, Andreassen IH, Høgåsen K, Hack CE, Harboe M.
    Mol Immunol; 1997 Jul 01; 34(10):719-29. PubMed ID: 9430199
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN.
    Piepers S, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol WL.
    J Neuroimmunol; 2010 Dec 15; 229(1-2):256-62. PubMed ID: 20920831
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.
    Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K.
    Clin Exp Immunol; 2001 May 15; 124(2):282-9. PubMed ID: 11422206
    [Abstract] [Full Text] [Related]

  • 17. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
    Wouters D, Wiessenberg HD, Hart M, Bruins P, Voskuyl A, Daha MR, Hack CE.
    J Immunol Methods; 2005 Mar 15; 298(1-2):35-45. PubMed ID: 15847795
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.